Cohort profile: POPPY II - a population-based cohort examining the patterns and outcomes of prescription opioid use in New South Wales, Australia.

Gisev, N; Pearson, S-A; Dobbins, T; Buizen, L; Murphy, T; Wilson, A; Blyth, F; Dunlop, A; Larney, S; Currow, DC; Mattick, RP; Degenhardt, L

Cohort profile: POPPY II - a population-based cohort examining the patterns and outcomes of prescription opioid use in New South Wales, Australia.

Gisev, N Pearson, S-A Dobbins, T Buizen, L Murphy, T Wilson, A Blyth, F Dunlop, A Larney, S Currow, DC Mattick, RP Degenhardt, L

Permalink

Publisher:: BMJ
Publication Type:: Journal Article
Citation:: BMJ Open, 2023, 13, (5), pp. e068310
Issue Date:: 2023-05-17

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download full textAdobe PDF (321.27 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Gisev, N
dc.contributor.author	Pearson, S-A
dc.contributor.author	Dobbins, T
dc.contributor.author	Buizen, L
dc.contributor.author	Murphy, T
dc.contributor.author	Wilson, A
dc.contributor.author	Blyth, F
dc.contributor.author	Dunlop, A
dc.contributor.author	Larney, S
dc.contributor.author	Currow, DC
dc.contributor.author	Mattick, RP
dc.contributor.author	Degenhardt, L
dc.date.accessioned	2023-09-05T06:32:06Z
dc.date.available	2023-09-05T06:32:06Z
dc.date.issued	2023-05-17
dc.identifier.citation	BMJ Open, 2023, 13, (5), pp. e068310
dc.identifier.issn	2044-6055
dc.identifier.issn	2044-6055
dc.identifier.uri	http://hdl.handle.net/10453/171923
dc.description.abstract	PURPOSE: The POPPY II cohort is an Australian state-based cohort linking data for a population of individuals prescribed opioid medicines, constructed to allow a robust examination of the long-term patterns and outcomes of prescription opioid use. PARTICIPANTS: The cohort includes 3 569 433 adult New South Wales residents who initiated a subsidised prescription opioid medicine between 2003 and 2018, identified through pharmacy dispensing data (Australian Pharmaceutical Benefits Scheme) and linked to 10 national and state datasets and registries including rich sociodemographic and medical services data. FINDINGS TO DATE: Of the 3.57 million individuals included in the cohort, 52.7% were female and 1 in 4 people were aged ≥65 years at the time of cohort entry. Approximately 6% had evidence of cancer in the year prior to cohort entry. In the 3 months prior to cohort entry, 26.9% used a non-opioid analgesic and 20.5% used a psychotropic medicine. Overall, 1 in 5 individuals were initiated on a strong opioid (20.9%). The most commonly initiated opioid was paracetamol/codeine (61.3%), followed by oxycodone (16.3%). FUTURE PLANS: The POPPY II cohort will be updated periodically, both extending the follow-up duration of the existing cohort, and including new individuals initiating opioids. The POPPY II cohort will allow a range of aspects of opioid utilisation to be studied, including long-term trajectories of opioid use, development of a data-informed method to assess time-varying opioid exposure, and a range of outcomes including mortality, transition to opioid dependence, suicide and falls. The duration of the study period will allow examination of population-level impacts of changes to opioid monitoring and access, while the size of the cohort will also allow examination of important subpopulations such as people with cancer, musculoskeletal conditions or opioid use disorder.
dc.format	Electronic
dc.language	eng
dc.publisher	BMJ
dc.relation	http://purl.org/au-research/grants/nhmrc/1138442
dc.relation	http://purl.org/au-research/grants/nhmrc/GNT1138442
dc.relation.ispartof	BMJ Open
dc.relation.isbasedon	10.1136/bmjopen-2022-068310
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	1103 Clinical Sciences, 1117 Public Health and Health Services, 1199 Other Medical and Health Sciences
dc.subject.classification	32 Biomedical and clinical sciences
dc.subject.classification	42 Health sciences
dc.subject.classification	52 Psychology
dc.subject.mesh	Adult
dc.subject.mesh	Humans
dc.subject.mesh	Female
dc.subject.mesh	Male
dc.subject.mesh	New South Wales
dc.subject.mesh	Australia
dc.subject.mesh	Papaver
dc.subject.mesh	Opioid-Related Disorders
dc.subject.mesh	Analgesics, Opioid
dc.subject.mesh	Prescription Drugs
dc.subject.mesh	Drug Prescriptions
dc.subject.mesh	Practice Patterns, Physicians'
dc.subject.mesh	Humans
dc.subject.mesh	Papaver
dc.subject.mesh	Opioid-Related Disorders
dc.subject.mesh	Analgesics, Opioid
dc.subject.mesh	Adult
dc.subject.mesh	Australia
dc.subject.mesh	New South Wales
dc.subject.mesh	Female
dc.subject.mesh	Male
dc.subject.mesh	Drug Prescriptions
dc.subject.mesh	Prescription Drugs
dc.subject.mesh	Practice Patterns, Physicians'
dc.subject.mesh	Adult
dc.subject.mesh	Humans
dc.subject.mesh	Female
dc.subject.mesh	Male
dc.subject.mesh	New South Wales
dc.subject.mesh	Australia
dc.subject.mesh	Papaver
dc.subject.mesh	Opioid-Related Disorders
dc.subject.mesh	Analgesics, Opioid
dc.subject.mesh	Prescription Drugs
dc.subject.mesh	Drug Prescriptions
dc.subject.mesh	Practice Patterns, Physicians'
dc.title	Cohort profile: POPPY II - a population-based cohort examining the patterns and outcomes of prescription opioid use in New South Wales, Australia.
dc.type	Journal Article
utslib.citation.volume	13
utslib.location.activity	England
utslib.for	1103 Clinical Sciences
utslib.for	1117 Public Health and Health Services
utslib.for	1199 Other Medical and Health Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/IMPACCT
utslib.copyright.status	open_access	*
dc.date.updated	2023-09-05T06:32:04Z
pubs.issue	5
pubs.publication-status	Published online
pubs.volume	13
utslib.citation.issue	5

Abstract:

PURPOSE: The POPPY II cohort is an Australian state-based cohort linking data for a population of individuals prescribed opioid medicines, constructed to allow a robust examination of the long-term patterns and outcomes of prescription opioid use. PARTICIPANTS: The cohort includes 3 569 433 adult New South Wales residents who initiated a subsidised prescription opioid medicine between 2003 and 2018, identified through pharmacy dispensing data (Australian Pharmaceutical Benefits Scheme) and linked to 10 national and state datasets and registries including rich sociodemographic and medical services data. FINDINGS TO DATE: Of the 3.57 million individuals included in the cohort, 52.7% were female and 1 in 4 people were aged ≥65 years at the time of cohort entry. Approximately 6% had evidence of cancer in the year prior to cohort entry. In the 3 months prior to cohort entry, 26.9% used a non-opioid analgesic and 20.5% used a psychotropic medicine. Overall, 1 in 5 individuals were initiated on a strong opioid (20.9%). The most commonly initiated opioid was paracetamol/codeine (61.3%), followed by oxycodone (16.3%). FUTURE PLANS: The POPPY II cohort will be updated periodically, both extending the follow-up duration of the existing cohort, and including new individuals initiating opioids. The POPPY II cohort will allow a range of aspects of opioid utilisation to be studied, including long-term trajectories of opioid use, development of a data-informed method to assess time-varying opioid exposure, and a range of outcomes including mortality, transition to opioid dependence, suicide and falls. The duration of the study period will allow examination of population-level impacts of changes to opioid monitoring and access, while the size of the cohort will also allow examination of important subpopulations such as people with cancer, musculoskeletal conditions or opioid use disorder.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/171923